TY - JOUR
AB - Inpharma 1542 - 17 Jun 2006 ■ A 007 may be effective for the treatment of cutaneous metastases from cancers, report researchers from the US. In this multicentre study, 27 patients with inoperable cutaneous lesions received topical A 007 at a mean dose of 0.1–11.5 mg/cm /week. The objective response rate was 26%. Minimum response or stabilisation of cancer was observed in an additional 19% of patients. The mean duration of response was 28.6 weeks. One patient had a response lasting 3.5 years. The most common adverse events associated with A-007 were itching, stinging and burning of the skin at application sites. Notably, these reactions occurred in patients whose skin lesions were shrinking. * Dekk-Tec, Barbara Ann Karmanos Cancer Institute; phase I/II for anal intraepithelial neoplasia and phase II for cervical intraepithelial neoplasia in the US. Eilender D, et al. 4,4’-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemotherapy and Pharmacology 57: 719-726, No. 6, Jun 2006 801067305 1173-8324/10/1542-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved Inpharma 17 Jun 2006 No. 1542 
TI - A 007 in cutaneous metastases from cancers
JF - Inpharma Weekly
DO - 10.2165/00128413-200615420-00011
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/a-007-in-cutaneous-metastases-from-cancers-p4ebcwSopb
SP - 7
EP - 7
VL - 1542
IS - 1
DP - DeepDyve
ER -